Abstract:Abstract Background: Alzheimer’s disease (AD) is pathologically characterized by extracellular deposition of amyloid β peptide (Aβ), intracellular neurofibrillary tangles (composed mainly of phosphorylated tau [p-tau]) and neuroinflammation. The pathogenic role of inflammatory activation in AD has been extensively studied; however, the underlying mechanisms remain unclear. In this project, we investigated how neuronal IKKβ/NF-kB regulates AD-associated pathologies in APP- and tau-transgenic AD mice. Methods: APP- and tau-transgenic mice were cross-bred with ikbkb-floxed and nex-cre knock-in mice to generate AD models with deletion of IKKβ specifically in neurons. After assessing cognitive function with the Morris water maze test, mice were analyzed for Aβ and p-tau levels, microglial numbers, transcription of inflammatory genes, apoptosis and synaptic protein levels in the brain by histological, biochemical and molecular biology methods. To explore pathogenic mechanisms, we analyzed the activity and/or protein levels of: 1) β- and γ-secretases, 2) tau-phosphorylating (e.g., GSK3β and p38α-MAPK) and dephosphorylating enzymes (e.g., PP2A and PP2B), and 3) autophagy-related proteins (e.g., LC3B, beclin1 and SQSTM1/p62). In addition, IKKβ-knockdown and wild-type SH-SY5Y cell lines were created to verify the in vivo results.Results: In APP-transgenic mice, neuronal deficiency of IKKβ decreased Aβ load, inflammatory activation, and apoptosis in the brain, and improved cognitive function and maintenance of synaptic proteins (e.g., PSD-95). IKKβ deficiency decreased BACE1 activity and protein in the brain and cultured neuronal cells. In tau-transgenic mice, neuronal deficiency of IKKβ decreased p-tau, shifted pro- to anti-inflammatory activation and inhibited autophagy in the brain. IKKβ deficiency increased expression of PP2A catalytic subunit isoform A, an enzyme dephosphorylating cerebral p-tau. However, deficiency of IKKβ in neurons did not alter the cognitive function and even increased apoptosis in the brain.Conclusions: Deficiency of IKKβ in neurons attenuates Aβ and p-tau loads in the brains of AD mice. As possible molecular mechanisms, IKKβ deficiency decreases BACE1 activity, thereby reducing Aβ production, and increases PP2A expression, promoting p-tau dephosphorylation. However, IKKβ deficiency protects neurons only in APP-transgenic mice, but not in tau-transgenic AD mice. Further studies are needed before IKKβ/NF-kB can be targeted for AD therapies.

Therapeutic targeting of immunometabolism in Alzheimer's disease reveals a critical reliance on Hexokinase 2 dosage on microglial activation and disease progression

Therapeutic targeting of immunometabolism reveals a critical reliance on hexokinase 2 dosage for microglial activation and Alzheimer's progression

Microglial hexokinase 2 deficiency increases ATP generation through lipid metabolism leading to β-amyloid clearance

Mitochondrial control of microglial phagocytosis by the translocator protein and hexokinase 2 in Alzheimer's disease

Increasing hexokinase 1 expression improves mitochondrial and glycolytic functional deficits seen in sporadic Alzheimer's disease astrocytes

Deficiency of IKKβ in neurons ameliorates Alzheimer’s disease pathology in APP- and tau-transgenic mice

Dual roles of hexokinase 2 in shaping microglial function by gating glycolytic flux and mitochondrial activity

Effect of Increased IL-1β on Expression of HK in Alzheimer's Disease.

Effect of Increased IL-1β on Expression of HK in Alzheimer’s Disease

Mitochondrial Regulation of Microglial Immunometabolism in Alzheimer's Disease

Imbalance in glucose metabolism regulates the transition of microglia from homeostasis to Disease Associated Microglia stage 1

The Neuro-Inflammatory Microenvironment: an Important Regulator of Stem Cell Survival in Alzheimer’s Disease

Positive Feedback Regulation of Microglial Glucose Metabolism by Histone H4 Lysine 12 Lactylation in Alzheimer's Disease

Mitochondrial Regulation of Microglial Immunometabolism in Alzheimer’s Disease

Genetic Ablation of Hematopoietic Cell Kinase Accelerates Alzheimer’s Disease–Like Neuropathology in Tg2576 Mice

Exploiting microglial and peripheral immune cell crosstalk to treat Alzheimer's disease

Targeting Microglia in Alzheimer's Disease: Pathogenesis and Potential Therapeutic Strategies

Exploiting microglial and peripheral immune cell crosstalk to treat Alzheimer’s disease

The immunometabolic reprogramming of microglia in Alzheimer's disease

Mtor-Mediated Immunometabolic Reprogramming Nanomodulators Enable Sensitive Switching of Energy Deprivation-Induced Microglial Polarization for Alzheimer’s Disease Management

Restoring hippocampal glucose metabolism rescues cognition across Alzheimer's disease pathologies